These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 28802755)

  • 21. Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan.
    Takeuchi N; Naito S; Ohkusu M; Abe K; Shizuno K; Takahashi Y; Omata Y; Nakazawa T; Takeshita K; Hishiki H; Hoshino T; Sato Y; Ishiwada N
    Epidemiol Infect; 2020 Apr; 148():e91. PubMed ID: 32299523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
    Webber C; Patton M; Patterson S; Schmoele-Thoma B; Huijts SM; Bonten MJ;
    Vaccine; 2017 Mar; 35(9):1266-1272. PubMed ID: 28173960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderly.
    van Werkhoven CH; Hollingsworth RC; Huijts SM; Bolkenbaas M; Webber C; Patterson S; Sanders EA; Bonten MJ
    Vaccine; 2016 Jun; 34(28):3275-82. PubMed ID: 27171754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in pathogens and pneumococcal serotypes causing community-acquired pneumonia in The Netherlands.
    Vestjens SMT; Wagenvoort GHJ; Grutters JC; Meek B; Aldenkamp AF; Vlaminckx BJM; Bos WJW; Rijkers GT; van de Garde EMW
    Vaccine; 2017 Jul; 35(33):4112-4118. PubMed ID: 28668570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019.
    Liapikou A; Konstantinidis A; Kossyvaki V; Skiadas J; Menegas D; Méndez C; Beavon R; Begier E; Gessner BD; Milionis H; Tsimihodimos V; Baxevanos G; Argiriadou T; Terrovitou C; Toumbis M;
    Hum Vaccin Immunother; 2022 Nov; 18(5):2079923. PubMed ID: 35703733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults.
    Chalmers JD; Campling J; Dicker A; Woodhead M; Madhava H
    BMC Pulm Med; 2016 May; 16(1):77. PubMed ID: 27169895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions.
    Jallow S; Madhi SA; Madimabe R; Sipambo N; Violari A; Kala U; Petersen K; Naidoo S; Verwey C; Moore DP; Nunes MC
    Vaccine; 2017 Aug; 35(34):4321-4329. PubMed ID: 28688781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pneumococcal serotype distribution in adults with invasive disease and in carrier children in Italy: Should we expect herd protection of adults through infants' vaccination?
    Azzari C; Cortimiglia M; Nieddu F; Moriondo M; Indolfi G; Mattei R; Zuliani M; Adriani B; Degl'Innocenti R; Consales G; Aquilini D; Bini G; Di Natale ME; Canessa C; Ricci S; de Vitis E; Mangone G; Bechini A; Bonanni P; Pasinato A; Resti M
    Hum Vaccin Immunother; 2016; 12(2):344-50. PubMed ID: 26647277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults.
    Suaya JA; Jiang Q; Scott DA; Gruber WC; Webber C; Schmoele-Thoma B; Hall-Murray CK; Jodar L; Isturiz RE
    Vaccine; 2018 Mar; 36(11):1477-1483. PubMed ID: 29429807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children.
    Angoulvant F; Levy C; Grimprel E; Varon E; Lorrot M; Biscardi S; Minodier P; Dommergues MA; Hees L; Gillet Y; Craiu I; Zenkhri F; Dubos F; Guen CG; Launay E; Martinot A; Cohen R
    Clin Infect Dis; 2014 Apr; 58(7):918-24. PubMed ID: 24532543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age.
    Isturiz RE; Hall-Murray C; McLaughlin JM; Snow V; Schmoele-Thoma B; Webber C; Thompson A; Scott DA
    Expert Rev Vaccines; 2018 Jan; 17(1):45-55. PubMed ID: 29183235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence, aetiology and serotype coverage for pneumococcal vaccines of community-acquired pneumonia in adults: a population-based prospective active surveillance study in Brazil.
    Duarte FG; Barberino MG; da Silva Moreira S; Reis JN; Spinardi JR; de Almeida RS; Allen KE; Alexander-Parrish R; Brim R; de Araújo Neto CA; Moreira ED
    BMJ Open; 2022 Apr; 12(4):e059824. PubMed ID: 35428648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distribution of 13-Valent pneumococcal conjugate vaccine serotype streptococcus pneumoniae in adults 50 Years and Older presenting with community-acquired pneumonia in Israel.
    Regev-Yochay G; Chowers M; Chazan B; Gonzalez E; Gray S; Zhang Z; Pride M
    Hum Vaccin Immunother; 2018; 14(10):2527-2532. PubMed ID: 30188760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rethinking number-needed-to-vaccinate for pneumococcal conjugate vaccines in older adults: Current and future implications.
    McLaughlin JM; Swerdlow DL; Isturiz RE; Jodar L
    Vaccine; 2017 Sep; 35(40):5360-5365. PubMed ID: 28863866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical features of adults with seven-valent-conjugated-vaccine-serotype pneumococcal pneumonia.
    Rodrigo C; Bewick T; Sheppard C; Greenwood S; Trotter C; Slack M; George R; Lim WS
    Vaccine; 2014 Mar; 32(13):1460-5. PubMed ID: 24508039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015.
    LeBlanc J; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang AL; Gillis HD; Martin I; Demczuk WH; LaFerriere C; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy A; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
    BMJ Open Respir Res; 2020 Mar; 7(1):. PubMed ID: 32188585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.
    Plosker GL
    Drugs; 2015 Sep; 75(13):1535-46. PubMed ID: 26242768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis.
    McLaughlin JM; Jiang Q; Gessner BD; Swerdlow DL; Sings HL; Isturiz RE; Jodar L
    Vaccine; 2019 Oct; 37(43):6310-6316. PubMed ID: 31522807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of the 13-valent pneumococcal conjugate vaccine against adult pneumonia in Italy: a case-control study in a 2-year prospective cohort.
    Prato R; Fortunato F; Cappelli MG; Chironna M; Martinelli D
    BMJ Open; 2018 Mar; 8(3):e019034. PubMed ID: 29581200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Community-Acquired Pneumococcal Pneumonia in Highly Vaccinated Population: Analysis by Serotypes, Vaccination Status, and Underlying Medical Conditions.
    Hyun H; Jang AY; Suh JW; Bae IG; Choi WS; Seo YB; Lee J; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Kim MJ; Song JY
    J Korean Med Sci; 2023 Oct; 38(42):e330. PubMed ID: 37904655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.